GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

Thalys Medical Technology Group 603716.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

15.15

+0.60%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Thalys Medical Technology Group

Its shares trade on Shanghai under the ticker 603716.SS. It has been listed since 31 October 2016. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.08bn and a net loss of CN¥207.3m. At that date it held total assets of CN¥1.80bn and shareholders' equity of CN¥944.7m.

Thalys Medical Technology Group, Inc. engages in the research, development, production, and sale of in vitro diagnostic products. The company is headquartered in Wuhan, Hubei. The company went IPO on 2016-10-31. Its product type includes purchased reagents and consumables, self-produced reagents and consumables, as well as purchased equipment. The firm mainly operates its business in domestic markets, with Hubei, Hunan, Jiangsu, Henan and Shanghai province as its major markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
31 Oct 2016
Employees
1,474

Leadership

Pay as last reported

  • Mr. Wei WenChairman of the Board, since 2015
  • Ms. Yan ShenChief Financial Officer
  • Mr. Zheng WangGeneral Manager, Director, since 2024
  • Ms. Li FanDeputy General Manager, Secretary of the Board, Director, since 2015
  • Mr. Yi LuDeputy General Manager
  • Mr. Jian QiuDeputy General Manager
  • Mr. Libo WanDeputy General Manager
  • Mr. Junming WangDeputy General Manager
  • Mr. Xiaoming WenDirector
  • Mr. Yicheng WenDirector
  • Mr. Xianwang ShiIndependent Director
  • Mr. Zhaoguo ZhangIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Thalys Medical Technology Group employs 1,474 full-time employees in Wuhan, Hubei.
  • The company's product portfolio includes purchased reagents, self-produced consumables, and equipment.
  • Major markets in Hubei, Hunan, Jiangsu, Henan, and Shanghai drive domestic sales.

Weaknesses

  • Thalys Medical Technology Group's business is primarily domestic, limiting international expansion.
  • The company relies on purchased reagents and equipment, increasing supply chain dependency.
  • Limited market presence outside Hubei, Hunan, Jiangsu, Henan, and Shanghai provinces.

Opportunities

  • Expanding into international markets could leverage Thalys' biotechnology expertise.
  • Growing demand for in vitro diagnostic products in China's health care sector.
  • Potential partnerships with domestic healthcare providers in major provinces.

Threats

  • Competition from established domestic biotechnology firms in Hubei and Shanghai.
  • Regulatory changes in China's health care industry could impact operations.
  • Economic downturns affecting domestic healthcare spending in key provinces.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.